Mifamurtide for the treatment of nonmetastatic osteosarcoma

Bibliography

• Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89
   PubMed Web of Science ®Google Scholar
• Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6. doi: 10.1186/1750-1172-2-6
   PubMed Web of Science ®Google Scholar
• Stiller CA, Bielack SS, Jundt G, Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2124-35
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J, Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15
   PubMed Web of Science ®Google Scholar
• Harris MB, Cantor AB, Goorin AM, Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87-92
   PubMedGoogle Scholar
• Kung FH, Pratt CB, Vega RA, Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71:1898-903
   PubMed Web of Science ®Google Scholar
• Miser JS, Kinsella TJ, Triche TJ, Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8
   PubMed Web of Science ®Google Scholar
• de Kraker J, Voute PA. Experience with ifosfamide in paediatric tumours. Cancer Chemother Pharmacol 1989;24(Suppl 1):S28-9
   PubMedGoogle Scholar
• Bacci G, Ferrari S, Longhi A, High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002;14:198-206
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-11
   PubMed Web of Science ®Google Scholar
• Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2006;2:333-43
   PubMedGoogle Scholar
• Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447-56
   PubMed Web of Science ®Google Scholar
• Bacci G, Lari S. Adjuvant and neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov 2001;86:253-68
   PubMedGoogle Scholar
• Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009;9:1035-49
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-8
   PubMed Web of Science ®Google Scholar
• Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther 2008;8:151-9
   PubMed Web of Science ®Google Scholar
• Anderson P, Kopp L, Anderson N, Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008;17:1703-15
   PubMed Web of Science ®Google Scholar
• Hughes DP. Novel agents in development for pediatric sarcomas. Curr Opin Oncol 2009;21:332-7
   PubMed Web of Science ®Google Scholar
• Nardin A, Lefebvre ML, Labroquere K, Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006;6:123-33
   PubMed Web of Science ®Google Scholar
• Fogler WE, Fidler IJ. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Int J Immunopharmacol 1987;9:141-50
   PubMed Web of Science ®Google Scholar
• Schroit AJ, Fidler IJ. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases. Prog Clin Biol Res 1982;102:347-55
   PubMedGoogle Scholar
• Kleinerman ES, Erickson KL, Schroit AJ, Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983;43:2010-14
   PubMed Web of Science ®Google Scholar
• Fogler WE, Fidler IJ. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res 1985;45:14-8
   PubMed Web of Science ®Google Scholar
• Galligioni E, Quaia M, Spada A, Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells. Int J Cancer 1993;55:380-5
   PubMedGoogle Scholar
• Asano T, McWatters A, An T, Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 1994;268:1032-9
   PubMed Web of Science ®Google Scholar
• Kurzman ID, Shi F, Vail DM, In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm 1999;14:121-8
   PubMed Web of Science ®Google Scholar
• Dieter P, Ambs P, Fitzke E, Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE. J Immunol 1995;155:2595-604
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Vail DM, Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:4249-58
   PubMed Web of Science ®Google Scholar
• Asano T, McIntyre BW, Bednarczyk JL, Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res 1995;7:253-7
   PubMed Web of Science ®Google Scholar
• Fogler WE, Wade R, Brundish DE, Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice. J Immunol 1985;135:1372-7
   PubMed Web of Science ®Google Scholar
• Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005;7:E20-41
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230-4
   PubMed Web of Science ®Google Scholar
• Gay B, Cardot JM, Schnell C, Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. J Pharm Sci 1993;82:997-1001
   PubMedGoogle Scholar
• Murray JL, Kleinerman ES, Cunningham JE, Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 1989;7:1915-25
   PubMed Web of Science ®Google Scholar
• Dieter P, Hempel U, Kamionka S, Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides. Mediators Inflamm 1999;8:295-303
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC, Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 1989;81:935-8
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 1991;9:259-67
   PubMed Web of Science ®Google Scholar
• Europeans Medicines Agency. Assessment report for Mepact. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/mepact/H-802-en6.pdf [Last accessed 25 September 2010]
   Google Scholar
• Strober W, Murray PJ, Kitani A, Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006;6:9-20
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Brown NO, Hart IR. Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously. J Biol Response Modif 1985;4:298-309
   PubMedGoogle Scholar
• Fidler IJ, Jessup JM, Fogler WE, Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 1986;46:994-8
   PubMedGoogle Scholar
• Sone S, Utsugi T, Tandon P, Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Cancer Immunol Immunother 1990;30:357-62
   PubMedGoogle Scholar
• Dinney CP, Tanguay S, Bucana CD, Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res 1995;15:585-92
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Fan D, Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 1989;9:75-88
   PubMedGoogle Scholar
• Goldbach P, Dumont S, Kessler R, In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Am J Physiol 1996;270:L429-34
   PubMed Web of Science ®Google Scholar
• Utsugi T, Nii A, Fan D, Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother 1991;33:285-92
   PubMedGoogle Scholar
• Galligioni E, Santarosa M, Favaro D, In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells. Tumori 1994;80:385-91
   PubMedGoogle Scholar
• Sone S, Tandon P, Utsugi T, Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Int J Cancer 1986;38:495-500
   PubMedGoogle Scholar
• Kleinerman ES, Murray JL, Snyder JS, Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 1989;49:4665-70
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Jia SF, Griffin J, Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992;10:1310-16
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Schneider M, Collins M, Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J Immunol 1985;135:1477-83
   PubMed Web of Science ®Google Scholar
• Xu Z, Fidler IJ. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol Immunother 1984;18:118-22
   PubMedGoogle Scholar
• Smith BW, Kurzman ID, Schultz KT, Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother 1993;8:137-44
   PubMedGoogle Scholar
• Bielack S, Kempf-Bielack B, Schwenzer D, Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 1999;211:260-70
   PubMedGoogle Scholar
• Hudson MM, Snyder JS, Jaffe N, In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 1988;48:5256-63
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Meyers PA, Raymond AK, Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother 1995;17:181-93
   PubMed Web of Science ®Google Scholar
• Killion JJ, Kleinerman ES, Wilson MR, Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res 1992;4:413-18
   PubMed Web of Science ®Google Scholar
• MEPACT 4 mg powder dor suspension for infusion: summary of product characteristics. Paris: IDM. In, 2010
   Google Scholar
• Provisor AJ, Ettinger LJ, Nachman JB, Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84
   PubMed Web of Science ®Google Scholar
• Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol 2008;26:3103-4; author reply 4-5
   PubMedGoogle Scholar
• Bielack SS, Marina N, Ferrari S, Osteosarcoma: the same old drugs or more? J Clin Oncol 2008;26:3102-3; author reply 4-5
   PubMedGoogle Scholar
• Goorin AM, Harris MB, Bernstein M, Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426-33
   PubMed Web of Science ®Google Scholar
• Chou AJ, Merola PR, Wexler LH, Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104:2214-21
   PubMed Web of Science ®Google Scholar
• Lafleur EA, Koshkina NV, Stewart J, Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004;10:8114-19
   PubMed Web of Science ®Google Scholar
• Urba WJ, Hartmann LC, Longo DL, Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 1990;50:2979-86
   PubMedGoogle Scholar
• Creaven PJ, Cowens JW, Brenner DE, Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Modif 1990;9:492-8
   PubMedGoogle Scholar
• Kleinerman ES, Gano JB, Johnston DA, Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995;18:93-9
   PubMed Web of Science ®Google Scholar
• Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother 1993;36:45-51
   PubMed Web of Science ®Google Scholar
• Fedorocko P, Hoferova Z, Hofer M, Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma 2003;50:176-84
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Raymond AK, Bucana CD, Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 1992;34:211-20
   PubMed Web of Science ®Google Scholar